The verdict
Our read at a glance.
Whether raising klotho in humans does anything, given that everything known about it comes from genetics, observation and animals.
- The signal
- The underlying science is real and active. Klotho-deficient mice show a syndrome resembling accelerated ageing, and overexpression extends lifespan in mice. In humans, carriers of the KL-VS variant have been reported to show better cognitive performance and other favourable outcomes, and circulating klotho has been examined as a biomarker across kidney disease, cardiovascular disease and cognition, with registered trials studying it as a measured marker in various conditions. Primate work injecting klotho and reporting cognitive improvement generated a further wave of interest. What is absent is the step that matters: no completed randomized trial has shown that administering klotho to humans improves any clinical outcome.
- The unknown
- Whether klotho is a cause or a readout. Almost all the human data are associations, and low klotho tracks kidney function closely, so it may be reporting on health rather than producing it.
- Our read
- A serious research programme with a gray market running years ahead of it. The biology is genuinely interesting and the human data are almost entirely observational, which is exactly the gap in which unverified injectables get sold. Being a real protein in a real ageing pathway is not evidence that injecting it helps.
The mechanism
How it works.
Klotho exists in two forms that do different jobs. Membrane-bound klotho, expressed mainly in kidney and choroid plexus, acts as an obligate co-receptor for fibroblast growth factor 23, which is how the body regulates phosphate and vitamin D. The extracellular domain can be cleaved and released as soluble klotho, which circulates and acts more like a hormone: it modulates insulin and IGF-1 signalling, influences Wnt and TGF-beta pathways, and has antioxidant effects. The lifespan phenotypes in mice are usually attributed to that soluble form dampening growth signalling - the same broad theme as caloric restriction and mTOR inhibition. The translational difficulty is size and delivery. Klotho is a large glycoprotein that does not cross membranes or survive digestion, so producing a therapeutic effect requires either injection of the protein, a way to raise endogenous production, or a small molecule that mimics its downstream signalling, and none of those has completed a human efficacy trial.
Safety & regulatory boundary
The consequential part.
No approved klotho therapy exists anywhere. It is a large glycoprotein, so oral products claiming to deliver it are not pharmacologically credible, and injectable material sold as klotho has no established identity, purity or dosing basis. Because it is a growth-modulating and phosphate-regulating protein, chronic administration outside trials carries risks that have not been characterised in people.
What's next
What we're watching.
The first controlled human administration trials, and whether the primate cognitive findings replicate.
Context
Why this is discussed.
The mouse data are among the most dramatic in ageing biology, and the human cognitive associations have been reported widely enough that products claiming to raise klotho are already being sold.
The evidence base
20 cited references.
Registered trials8
ClinicalTrials.gov · NOT_YET_RECRUITING · 2026-08-05
ClinicalTrials.gov · PHASE3 · COMPLETED · 2025-02-03
ClinicalTrials.gov · NA · RECRUITING · 2026-03-09
ClinicalTrials.gov · NA · COMPLETED · 2023-07-20
ClinicalTrials.gov · EARLY_PHASE1 · RECRUITING · 2020-09-02
ClinicalTrials.gov · PHASE1/PHASE2 · ACTIVE_NOT_RECRUITING · 2026-02-24
ClinicalTrials.gov · PHASE2 · NOT_YET_RECRUITING · 2026-07-01
ClinicalTrials.gov · PHASE1 · COMPLETED · 2024-02-29
Indexed literature (PubMed)12
Prud'homme GJ et al. · Front Aging · 2022
Gaitán JM et al. · Front Endocrinol (Lausanne) · 2021
Kuro-O M · Vitam Horm · 2021
Abraham CR et al. · Vitam Horm · 2016
Abraham CR et al. · Ageing Res Rev · 2022
Capasso G et al. · Nat Rev Nephrol · 2025
Vo HT et al. · Brain Plast · 2018
Chen CD et al. · J Mol Neurosci · 2018
Dubal DB et al. · Cell Rep · 2014
Torbus-Paluszczak M et al. · Neurol Sci · 2018
Castner SA et al. · Nat Aging · 2023
Chen CD et al. · PLoS One · 2020
Keep reading